Last reviewed · How we verify
Any antihypertensive medication alone or in combination
At a glance
| Generic name | Any antihypertensive medication alone or in combination |
|---|---|
| Also known as | Olmesartan, Irbesartan, Candesartan, Telmisartan, Valsartan |
| Sponsor | University of Vigo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Immediate Fracture Risk After Antihypertensive Drug Initiation
- Hydrochlorothiazide and Risk of Skin Cancer
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: